Login / Signup

Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.

Pamela N MunsterNicholas O IannottiDaniel C ChoJoanne M JeterLiza C VillaruzGeoffrey Thomas GibneyFrank Stephen HodiNiharika B MettuMark JonesJill BowmanMichael SmithMani LakshminarayananSteven J O'Day
Published in: Cancer research communications (2023)
PD-1 blockade combined with targeted therapies have demonstrated encouraging preclinical activity. In this phase I study, patients with advanced solid tumors treated with pembrolizumab (PD-1 inhibitor) and either itacitinib (JAK1 inhibitor) or parsaclisib (PI3Kδ inhibitor) experienced limited clinical activity beyond that expected with checkpoint inhibition alone and showed little effect on T-cell infiltration in the tumor. These results do not support continued development of these combinations.
Keyphrases
  • advanced non small cell lung cancer
  • dna damage
  • stem cells
  • mesenchymal stem cells
  • cell therapy
  • tyrosine kinase